Melis V et al., 2015-06: ANIMAL: in two transgenic tau mouse lines, oral MTC/LMTX dose-dependently restored learning and reduced tau-reactive neurons – the in-vivo basis of the tau programme.
These data establish that diaminophenothiazine compounds, like MT, can reverse both spatial and motor learning deficits and reduce the underlying tau pathology, and therefore offer the potential for treatment of tauopathies.
Melis V et al., 2015-06: ANIMAL: in two transgenic tau mouse lines, oral MTC/LMTX dose-dependently restored learning and reduced tau-reactive neurons – the in-vivo basis of the tau programme. ANIMAL ONLY (transgenic tau mice, lines 1 and 66). Universities of Aberdeen and Charité Berlin; several authors are TauRx/Wischik lab members. Dose: MTC or LMTX 5-75 mg/kg oral, 3-8 weeks; minimum effective 35 mg/kg (MTC) and 9 mg/kg (LMTX) in Line 1, 4 mg/kg in Line 66. Comparator: vehicle. Endpoint is tau load, not amyloid. Funder/COI not stated in abstract. Study type: animal.
